Kintor Pharma shifts from cancer drugs to cosmetics as funds run low
The cash-strapped biotech has begun generating its first revenue from over-the-counter cosmetic treatments, as it pivots away from its original oncology drugs Key Takeaways: Kintor Pharma is shifting from its…
BRIEF: Yonghe Medical’s loss narrows on improved efficiency
Hair transplant specialist Yonghe Medical Group Co. Ltd. (2279.HK) said on Tuesday it expects its net loss for 2024 to narrow significantly to 246 million yuan ($33.73 million) or less,…
Stock disconnect triggers investor exodus from CStone Pharma
The share price fell nearly 40% in a week after the drugs company was dropped from a scheme allowing mainland investors to trade Hong Kong-listed stocks Key Takeaways: CEO Jason…
Yonghe Medical’s share repurchase gets results, but can’t hide a receding profit line
A big run-up in wages and marketing costs related to its aggressive expansion pulled the hair restoration company into the red in the first half of this year Key Takeaways:…
FAST NEWS: Yonghe Medical swings to red, sending shares to new low
The latest: Hair transplant specialist Yonghe Medical Group Co. Ltd. (2279.HK) issued a profit warning last Friday, saying it expects a net loss of about 240 million yuan ($33.6 million) in the first half…
FAST NEWS: Yonghe Medical Expects Half-year Profit To Plunge 50% to 73%
The latest: Hair transplant specialist Yonghe Medical Group Co. Ltd. (2279.HK) issued a profit warning last last week, saying it expects a net profit of about 11 million yuan ($16.2 million) to…
FAST NEWS: Yonghe Medical Grows Hair Care Business, But Profit Falls
The latest: Hair transplant specialist Yonghe Medical Group Co. Ltd. (2279.HK) said late on Thursday that its profit fell 26.4% last year to 120 million yuan ($18.9 million), equal to…
Recent Articles
RELATED ARTICLES
-
Plenty of room for growth in China’s hair transplant market
-
A blockbuster cancer drug? TYK’s claims go under the microscope
2410.HK
-
Everest gets boost from core product Nefecon’s inclusion in China’s national health plan
1952.HK
- Cancer drug maker Genfleet joins Hong Kong IPO influx
- Cloudbreak Pharma sets sights on Hong Kong IPO after license deal
-
Investors cheer Akeso’s revenue milestone, even as it returns to the red
9926.HK
